---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-001249"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2025-01-06T23:59:59+00:00"
generated_at: "2026-05-28T10:40:40.891351+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Relmada appoints Paul Kelly as COO; amends NEO employment agreements, suspends retention payments

## Summary
- Paul Kelly named COO effective Jan 1, 2025; salary $476K, target bonus 40%, severance 6 months.
- Amended employment agreements for CEO Traversa, CFO Shenouda, CAO Ence extend option exercisability upon termination.
- NEOs receive no salary increases for FY2025, no cash bonuses or long-term incentive awards for FY2024.
- All further retention payments for NEOs and Kelly suspended until Board approves strategic initiatives.

## SEC filing metadata
- accession: 0001213900-25-001249
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2025-01-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390025001249/0001213900-25-001249-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390025001249/ea0226941-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-001249
- JSON: https://secwatch.observer/filing/0001213900-25-001249.json
- Plain text: https://secwatch.observer/filing/0001213900-25-001249.txt

## Key facts
- Executive change
  Paul Kelly was elected as Chief Operating Officer at RELMADA THERAPEUTICS, INC..
  - Action: elected
  - Role: Chief Operating Officer
  source text: Paul Kelly was elected by the Board of Directors (the “Board”) to the position of Chief Operating Officer of Relmada Therapeutics, Inc. (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1553643/000121390025001249/0001213900-25-001249-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.